Lazard Asset Management LLC raised its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 37.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,996 shares of the company's stock after acquiring an additional 12,583 shares during the quarter. Lazard Asset Management LLC owned approximately 0.14% of TransMedics Group worth $2,867,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the 4th quarter valued at approximately $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter valued at approximately $33,000. Sachetta LLC bought a new stake in TransMedics Group during the 4th quarter valued at approximately $40,000. AlphaQuest LLC bought a new stake in TransMedics Group during the 4th quarter valued at approximately $52,000. Finally, Arcadia Investment Management Corp MI bought a new stake in TransMedics Group during the 4th quarter valued at approximately $72,000. 99.67% of the stock is owned by institutional investors.
TransMedics Group Stock Performance
Shares of NASDAQ TMDX traded up $2.61 during midday trading on Tuesday, hitting $124.71. 647,864 shares of the stock traded hands, compared to its average volume of 1,354,160. The firm has a 50-day moving average of $85.09 and a two-hundred day moving average of $76.09. The firm has a market capitalization of $4.22 billion, a P/E ratio of 132.67 and a beta of 1.91. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have recently commented on TMDX shares. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reissued an "overweight" rating and issued a $125.00 price target (up from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Finally, Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $126.70.
Check Out Our Latest Research Report on TMDX
Insider Buying and Selling
In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is owned by insiders.
About TransMedics Group
(
Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Recommended Stories
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
